---
schema_version: "secwatch.filing_event.v1"
accession: "0001551152-22-000038"
form_type: "8-K"
ticker: "ABBV"
cik: "0001551152"
company_name: "AbbVie Inc."
filed_at: "2022-10-28T23:59:59+00:00"
generated_at: "2026-06-22T22:37:21.678113+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# AbbVie Q3 adj. EPS $3.66 (+29.3%) on revenue $14.8B; raises 2023 dividend 5%

## Summary
- GAAP diluted EPS $2.21 (+24.2%); adjusted diluted EPS $3.66 (+29.3%), includes $0.02 IPR&D hit.
- Total net revenues $14.812B (+3.3% reported, +5.4% operational). Immunology $7.651B (+14.6%).
- U.S. Humira $4.956B (+7.4%); international Humira $603M (-25.9%) due to biosimilars; Skyrizi $1.397B, Rinvoq $695M.
- Hematologic oncology $1.650B (-11.7%) with Imbruvica $1.135B (-17.4%); Neuroscience $1.672B (+6.7%), Aesthetics $1.301B (+4.0%).
- Narrows FY2022 adj. EPS guidance to $13.84-$13.88 (from $13.76-$13.96); announces 5% dividend increase starting Feb 2023.

## SEC filing metadata
- accession: 0001551152-22-000038
- form_type: 8-K
- ticker: ABBV
- cik: 0001551152
- company_name: AbbVie Inc.
- filed_at: 2022-10-28T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1551152/000155115222000038/0001551152-22-000038-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1551152/000155115222000038/abbv-20221028.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001551152-22-000038
- JSON: https://secwatch.observer/filing/0001551152-22-000038.json
- Plain text: https://secwatch.observer/filing/0001551152-22-000038.txt

## Key facts
- Earnings Releases
  AbbVie Inc. reported the third quarter ended September 30, 2022 results: revenue $14.812 Billion, EPS $3.66. Guidance reaffirmed.
  - Period: the third quarter ended September 30, 2022
  - Revenue: $14.812 Billion
  - EPS: $3.66
  - Guidance: reaffirmed
  - Result: reported results
  source text: • Reports Third-Quarter Diluted EPS of $2.21 on a GAAP Basis, an Increase of 24.2 Percent; Adjusted Diluted EPS of $3.66, an Increase of 29.3 Percent; These Results Include an Unfavorable Impact of $0.02 Per Share related to Acquired IPR&D and Milestones Expense 1 • Delivers Third-Quarter Net Revenues of $14.812 Billion, an Increase of 3.3 Percent on a Reported Basis and 5.4 Percent Operationally
  evidence_url: https://www.sec.gov/Archives/edgar/data/1551152/000155115222000038/0001551152-22-000038-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.